Bylined Articles and Infographics

Bylined Articles and Features

2018

Applied Clinical Trials – Maximizing Immuno-Oncology Clinical Trial Success
by Luke S. Gill, Vice President, Oncology, Clinical Development Services

Life Science Leader – As Cancer Immune Therapies Advance, 4 Biomarker Trends To Watch
by Nina Baluja, M.D., Senior Medical Director

EE Times – Implants Raise Security Awareness
by Joanne Emmett, Vice President, Medical Devices

PM360 – Best Practices for Forging Strategic Sponsor-CRO Relationships
by Krista Armstrong, Ph.D., Vice President & Head of Neuroscience

Drug Development & Delivery – Device Regulations, Early Preparation Will Pay Big Dividends as EU Enacts New EU Device Regulations
by Joanne Emmett, Vice President, Medical Devices

2017

PharmaVoice – Trending 2018: Rare Diseases
contribution by Angi Robinson, Executive Director, Strategic Development Department, Rare Disease & Pediatrics

Applied Clinical Trials – Vaccine-Induced Specific Immune Response Offers an Avenue to Potentiate Responses to Immune Checkpoint Inhibitor Therapy
by Nina Baluja, M.D., Senior Medical Director III, Medical Services

Clinical Leader – Maximizing Immuno-Oncology Clinical Trial Success
by Luke S. Gill, Executive Director, Oncology, Strategic Development

The Dermatologist, New Treatment Options Improve the Outlook for Acne Patients
by Howard Welgus, M.D., Executive Director, Medical Affairs, Medical Services

As new EU device regulations phase in, here’s what you should do now
by Joanne Emmett, Vice President, Medical Devices

Life Sciences IP Review – Medical devices new rules: the clock is ticking [Subscription needed]
by Joanne Emmett, Vice President, Medical Devices

PharmaVoice – Rare Recruitment
contribution by Juliet M. Moritz, MPH, Executive Director, Patient Engagement and Strategic Development and Angi Robinson, Executive Director, Strategic Development Department, Rare Disease & Pediatrics

PM360 – Patient Advocates Assume a Large Role as Orphan Drug Development Expands
by Juliet M. Moritz, MPH, Executive Director, Patient Engagement and Strategic Development

Applied Clinical Trials – The Growing Role of Performance Incentives Between Sponsors, CROs
by Sean Russell, Chief Commercial Officer

Applied Clinical Trials – Drug Developers Embrace the Rising Prominence – and Influence – of Patient Advocacy
by Juliet M. Moritz, MPH, Executive Director, Strategic Development Department, Rare Diseases

Life Science Leader – Orphan Drug Incentives & Innovations On The Rise
by Angi Robinson, Executive Director, Strategic Development Department, Rare Disease & Pediatrics

2016

SCRIP – The CRO View: Sharing Opportunity Vs Risk In Drug Development
by Sean Russell, Chief Commercial Officer

Rare Disease Research: It Pays to Engage
interview with Juliet M. Moritz, MPH, Executive Director, Strategic Development Department, Rare Diseases

Clinical Leader – Finally Getting It Right: The Future Of Forecasting And Making Investigator Payments
by Charlie Nicholson, Chief Financial Officer

PharmaLive – Incentives, Opportunities Abound as Orphan Drug Demand Grows
by Lisa N. Pitt, PharmD, MSJ, Vice President, Global Regulatory Affairs, and
Angi Robinson, Executive Director, Strategic Development Department, Rare Disease & Pediatrics

Life Sciences IP Review – Running an Efficient Clinical Drug Trial
by Charlie Nicholson, Chief Financial Officer

Drug Development & Discovery – The Opportunity in Sharing Risk: A Productive Trend in Clinical Trials
by Sean Russell, Chief Commercial Officer

CenterWatch Weekly – 3 Questions with Juliet Moritz
by Juliet M. Moritz, MPH, Executive Director, Strategic Development Department, Rare Diseases

 

 

Infographics

Orphan Drugs & Rare Disease

Phone Us Now
Email Us Now